Today: 11 June 2026
Dutch Bros (BROS) beats Q3 2025, raises full‑year sales outlook to $1.61B–$1.615B — Stock moves today (Nov. 5, 2025)
5 November 2025
2 mins read

Dutch Bros (BROS) beats Q3 2025, raises full‑year sales outlook to $1.61B–$1.615B — Stock moves today (Nov. 5, 2025)

Key takeaways (today): Revenue +25% YoY to $423.6M; adjusted EPS $0.19 vs. ~$0.17 expected; system same‑shop sales +5.7%; FY25 revenue outlook lifted; 160 shop openings targeted in 2025 and ~175 in 2026.

What happened today

Dutch Bros (NYSE: BROS) reported third‑quarter 2025 results after the bell, delivering 25% year‑over‑year revenue growth to $423.6 million and systemwide same‑shop sales up 5.7% (company‑operated +7.4%). Management said this marked the fifth consecutive quarter of positive transaction growth and noted systemwide AUVs at record highs.

The company raised full‑year 2025 revenue guidance to $1.61B–$1.615B (from the prior $1.59B–$1.60B range communicated with Q2 results), reiterated adjusted EBITDA of $285M–$290M, and maintained capex at $240M–$260M. Dutch Bros continues to target ~160 total system shop openings in 2025 and ~175 in 2026.

CEO Christine Barone said the quarter reflected “our fifth consecutive quarter of positive transaction growth,” underscoring momentum heading into Q4. Business Wire


By the numbers (Q3 2025)

  • Revenue: $423.6M (+25.2% YoY).
  • GAAP diluted EPS:$0.14 (vs. $0.11 YoY).
  • Adjusted EPS:$0.19 (vs. ~$0.17 consensus preview).
  • Same‑shop sales:+5.7% systemwide; +7.4% company‑operated; transaction growth +4.7% systemwide and +6.8% company‑operated.
  • Shop development:38 new shops opened in Q3 (34 company‑operated) across 17 states; 1,081 locations in 24 states as of Sep. 30, 2025.
  • Profitability mix: Adjusted EBITDA $78.0M (+22.3% YoY); company‑operated revenue $392.8M (+27.4% YoY).

Beat vs. expectations: Multiple outlets pegged consensus at ~$414–$415M revenue and ~$0.17 EPS, implying top‑ and bottom‑line beats on today’s print ($423.6M / $0.19 adjusted EPS).


Guidance & 2026 outlook (updated today)

  • FY25 revenue:$1.61B–$1.615B (raised).
  • FY25 same‑shop sales: ~+5%.
  • FY25 adjusted EBITDA:$285M–$290M (unchanged).
  • FY25 capex:$240M–$260M (unchanged).
  • Openings:~160 total system shops in 2025; ~175 targeted in 2026.

Context: The revenue range was previously $1.59B–$1.60B after Q2; today’s update pushes that higher.


How the stock is trading today

Into the print and after hours, BROS shares were volatile. As of the latest tick, the stock traded around the mid‑$50s with intraday range roughly $52.68–$58.00 and heavy volume versus average. The 52‑week range stands at $32.69–$86.77.

Analyst snapshot: Ahead of results, consensus looked for ~$414.7M revenue and $0.17 EPS; 12‑month price targets recently hovered in the mid‑to‑upper $70s (directional, varies by source).


Why it matters to investors

  • Transactions are driving: Dutch Bros’ strategy continues to grow traffic, not just ticket, a healthier mix for long‑term share gains.
  • Unit expansion intact: With 1,081 shops and a clear pipeline, Dutch Bros is still in early innings of national build‑out relative to larger peers.
  • Profit algorithm: Despite pre‑opening costs pressuring some margins, SG&A leverage and scale should support the $285M–$290M adjusted EBITDA goal.

What to watch next (today)

  • Earnings call:5:00 p.m. ET, Nov. 5 — prepared remarks and Q&A with CEO Christine Barone and CFO Joshua Guenser; slides to post on the IR site. Expect color on Q4 traffic, mobile order adoption, and the 2026 build cadence.

Quick FAQ

What moved BROS today? A Q3 beat on revenue and adjusted EPS plus a raised FY25 sales outlook.

How big is Dutch Bros now?1,081 locations across 24 states as of Sept. 30, 2025.

Where is the stock trading relative to history? Well below the 52‑week high ($86.77) but above the 52‑week low ($32.69).


Disclosure: This article is for informational purposes only and is not investment advice. Always do your own research.

Stock Market Today

  • Parabilis Medicines IPO Surges 58% on Nasdaq, Raises $670 Million
    June 10, 2026, 6:10 PM EDT. Parabilis Medicines (PBLS) soared 58% in its Nasdaq debut, closing at $31.60 against a $20 IPO price, after upsizing its offering to raise $670 million, surpassing expectations. The biopharma's shares opened strong, hitting a high of $34.02 amid high demand, with an additional $75 million from Regeneron in a private placement boosting total proceeds. Parabilis focuses on Helicon peptides targeting difficult protein sites, with a crucial Phase 3 tumor trial expected in early 2027. The IPO marks one of the largest venture-backed biotech offerings in 2026, signaling renewed investor interest and confidence in the biotech sector's health.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Upstart Holdings’ AI Lending Revolution: Surging Growth, Stock Turmoil, and What’s Next for UPST
Previous Story

Upstart Holdings’ AI Lending Revolution: Surging Growth, Stock Turmoil, and What’s Next for UPST

Interstellar Comet 3I/ATLAS: A Visitor from Beyond the Solar System
Next Story

Comet 3I/ATLAS today (6 Nov 2025): China’s Mars orbiter snaps new photos as the interstellar visitor turns bluer and shows puzzling acceleration

Go toTop